Medicare Enrolled

Dr. Elvin Garcia, M.D.

Rheumatology · McAllen, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
811 E FERN AVE STE 1, McAllen, TX 78501
9566302114
In practice since 2006 (19 years)
NPI: 1871547596 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Garcia from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Garcia? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Garcia

Dr. Elvin Garcia is a rheumatology in McAllen, TX, with 19 years in practice. Based on federal Medicare data, Dr. Garcia performed 95,355 Medicare services across 6,441 unique beneficiaries.

Between the years covered by Open Payments, Dr. Garcia received a total of $95,918 from 15 pharmaceutical and/or device companies across 156 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Garcia is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 16% volume in TX$ $95,918 industry payments

Medicare Practice Summary

Medicare Utilization ↗
95,355
Medicare services
Top 16% in TX for rheumatology
6,441
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,019 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Tocilizumab injection (Actemra)29,940$5$6
Dexamethasone injection (steroid)25,173$0$0
Injection, rituximab, 10 mg7,411$63$100
Denosumab injection (Prolia/Xgeva)6,541$18$25
Infliximab infusion (Remicade)6,520$26$121
Abatacept infusion (Orencia)6,400$34$60
Office visit, established patient (30-39 min)1,240$86$145
Administration of chemotherapy into vein, each additional hour953$21$55
Office visit, established patient, complex (40-54 min)918$117$180
Injection, ketorolac tromethamine, per 15 mg813$0$5
Red blood cell sedimentation rate, to detect inflammation, non-automated761$4$10
C-reactive protein test (inflammation marker)747$5$15
Administration of chemotherapy into vein, 1 hour or less708$95$250
Drug injection, under skin or into muscle696$10$30
Injection, diphenhydramine hcl, up to 50 mg677$1$2
Injection of additional new drug or substance into vein672$11$20
Complete blood count (CBC) with differential604$8$25
Joint injection, major joint411$57$114
Injection, methylprednisolone acetate, 40 mg411$6$10
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose362$57$105
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle357$52$90
Injection of trigger points, 3 or more muscles255$42$90
Rheumatoid factor analysis254$6$15
X-ray of knee, 1-2 views223$25$50
X-ray of hand, 2 views210$23$50
Urinalysis, manual191$3$15
X-ray of wrist, 2 views178$25$50
Injection of trigger points, 1-2 muscles141$36$80
Bone density scan (DEXA)139$36$100
X-ray of foot, 2 views137$21$50
X-ray of ankle, 2 views123$25$50
Measurement of antibody for assessment of autoimmune disorder, any method109$18$35
Screening test for autoimmune disorder108$12$25
Measurement of dna antibody, native or double stranded108$13$30
X-ray of lower and sacral spine, 2-3 views107$27$50
New patient office visit (45-59 min)99$107$250
Vitamin D level test97$29$50
Office visit, established patient (20-29 min)95$67$126
Shoulder X-ray, 2+ views91$26$50
Chest X-ray, 2 views82$24$50
X-ray of upper spine, 2-3 views63$29$50
X-ray of middle spine, 2 views63$25$50
X-ray of both hips, 2 views63$30$100
X-ray of elbow, minimum of 3 views46$25$50
Aspiration and/or injection of fluid from medium joint22$34$80
Hip X-ray, 2-3 views19$36$50
Screening test for strep antibody (strep throat)17$6$15
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
13.5% high complexity
79.2% medium
7.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$95,918
Total received (2018-2024)
Avg $13,703/year across 7 years
Top 7% in TX for rheumatology
15
Companies
156
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$95,066 (99.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$852 (0.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$12,825
2023
$22,411
2022
$16,706
2021
$28,764
2020
$836
2019
$4,254
2018
$10,121

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Horizon Therapeutics plc
$42,551
Aurinia Pharma U.S., Inc.
$22,551
Amgen Inc.
$12,434
Horizon Pharma plc
$9,873
GlaxoSmithKline, LLC.
$7,520
Genentech USA, Inc.
$224
Janssen Biotech, Inc.
$154
Novartis Pharmaceuticals Corporation
$137
ANI Pharmaceuticals, Inc.
$134
AbbVie, Inc.
$113
Celgene Corporation
$112
E.R. Squibb & Sons, L.L.C.
$42
PFIZER INC.
$39
Boehringer Ingelheim Pharmaceuticals, Inc.
$18
Lilly USA, LLC
$17
Top 3 companies account for 80.8% of total payments
Associated products mentioned in payments ›
BENLYSTA · DUEXIS · Humira · KRYSTEXXA · LEQVIO · LUPKYNIS · OFEV · ORENCIA · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Rituxan · TALTZ · TREMFYA · Tavneos · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (99%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for rheumatology in TX.

Equivalent to $101 per 100 Medicare services performed
Looking for a rheumatology in McAllen?
Compare rheumatologys in the McAllen area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
8
Per 100K population
0.9
County median income
$52,281
Nearest hospital
RIO GRANDE REGIONAL HOSPITAL
3.7 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Garcia is a mixed practice specialist, with above-average Medicare volume (top 16% in TX), and high industry engagement (speaking/promotional, top 7%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Garcia experienced with tocilizumab injection (actemra)?
Based on Medicare claims data, Dr. Garcia performed 29,940 tocilizumab injection (actemra) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Garcia receive payments from pharmaceutical companies?
Yes. Dr. Garcia received a total of $95,918 from 15 companies across 156 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Garcia's costs compare to other rheumatologys in McAllen?
Dr. Garcia's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Garcia) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →